Propanc Biopharma Inc (PPCB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 9 | 21 | 6 | 72 | 7 |
| Receivables | 3 | 3 | 5 | 4 | 3 |
| Other current assets | 0 | 1 | 0 | 123 | 116 |
| TOTAL | $22 | $25 | $13 | $211 | $146 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 42 | 47 | 25 | 31 | 34 |
| TOTAL | $42 | $47 | $25 | $31 | $35 |
| Total Assets | $64 | $72 | $37 | $242 | $180 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 424 | 266 | 146 | 132 | 113 |
| Accounts payable and accrued liabilities | 1,239 | 1,213 | 1,188 | 1,158 | 1,081 |
| Accrued Expenses | 987 | 887 | 849 | 756 | 668 |
| Other current liabilities | 843 | 803 | 768 | 874 | 727 |
| TOTAL | $4,101 | $3,793 | $3,688 | $3,762 | $3,133 |
| Non-Current Liabilities | |||||
| Long Term Debt | 71 | 59 | 47 | 35 | 23 |
| Other Non-Current Liabilities | 0 | 0 | 2 | 8 | 13 |
| TOTAL | $71 | $59 | $49 | $43 | $37 |
| Total Liabilities | $4,172 | $3,851 | $3,737 | $3,806 | $3,170 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 13 | 11 | 3 | 1 | 0 |
| Common Shares | 688 | 0 | 110 | 36 | 16 |
| Retained earnings | -67,053 | -66,698 | -66,340 | -65,797 | -65,178 |
| Other shareholders' equity | 1,124 | 1,223 | 1,293 | 1,179 | 1,322 |
| TOTAL | $-4,108 | $-3,779 | $-3,700 | $-3,564 | $-2,989 |
| Total Liabilities And Equity | $64 | $72 | $37 | $242 | $180 |